SAN FRANCISCO – Patients with alcohol use disorder reported a substantial decrease in drinking days, drinks per drinking day, and cravings in an ongoing of psilocybin at New York University.
Alcohol is killing more adults in the U.S. than the opioid epidemic according to the Institute for Health Metrics and Evaluation at the University of Washington.
Having that wind-down glass of wine when you get home from work may be harming your health. That’s because, according to a large-scale, global meta-analysis of research published August 23, 2018 in The Lancet, there’s a chance that no amount of alcohol is safe.
To minimize health risks, the optimal amount of alcohol someone should consume is none. That’s the simple, surprising conclusion of a massive study, co-authored by 512 researchers from 243 institutions, published Thursday in the prestigious journal the Lancet.
A University of Rhode Island College of Pharmacy professor is working to change that, and a new clinical trial is right around the corner. Fatemeh Akhlaghi, the Ernest Mario Distinguished Chair in Pharmaceutics, is part of a team working to develop a novel medication to treat alcohol use disorder, the term scientists and health practitioners use.